Tango Therapeutics, INC

Tango Therapeutics has filed an update to its at-the-market offering program, increasing the potential aggregate offering price to $400 million and terminating a prior supplement.

Tango Therapeutics announced strong Phase 1/2 data for vopimetostat in pancreatic cancer, positioning it for Phase 3 development, and reported a cash position of $1.0 billion as of June 30, 2026.

Tango Therapeutics, Inc. has filed an 8-K/A to amend its previous filing, detailing the separation agreement for Executive Chair Dr. Barbara Weber, effective August 3, 2026.

Tango Therapeutics reports the departure of Executive Chair Dr. Barbara Weber, effective August 3, 2026, with standard separation terms outlined.

Tango Therapeutics announced a public offering of common stock and pre-funded warrants expected to raise approximately $566.5 million.

Tango Therapeutics announced highly encouraging initial safety and efficacy data from its Phase 1/2 combination trial of vopimetostat with RAS(ON) inhibitors in pancreatic cancer patients.

Tango Therapeutics announced promising efficacy data for its vopimetostat combination therapy in pancreatic cancer, alongside significant increases in R&D spending and continued net losses, highlighting ongoing capital requirements.

Tango Therapeutics reports Q1 2026 results, detailing ongoing clinical trials, financial position, and strategic pipeline advancements.

Tango Therapeutics announced its Q3 2025 financial results, highlighting positive clinical data for vopimetostat and a strong cash runway into 2028 following a recent $212 million capital raise.

Tango Therapeutics reported a wider net loss in Q2 2025, driven by decreased collaboration revenue and increased R&D for key oncology programs, while extending its cash runway into Q1 2027.

Tango Therapeutics reports a net loss of $39.9 million for Q1 2025 and anticipates funding operations into Q1 2027 with existing cash reserves.

Tango Therapeutics announced its third quarter 2024 financial results, highlighting progress in its clinical programs and providing updates on its pipeline.

Tango Therapeutics, Inc. filed its annual 10-K report, highlighting positive clinical data for vopimetostat and TNG260, strategic collaborations, and a cash runway into 2028.

Tango Therapeutics' 10-K filing summarizes the company's financial results for 2024, highlights clinical progress with TNG462 and TNG260, and outlines strategic plans for advancing its precision oncology pipeline.

Tango Therapeutics' 2023 annual report highlights progress in its precision oncology pipeline, including clinical trials for multiple drug candidates and ongoing research collaborations.

Adam Crystal, President, R&D of Tango Therapeutics, Inc., sold 27,000 shares of common stock on August 3, 2026.

Tango Therapeutics President of R&D, Adam Crystal, reported transactions involving the sale of company stock and the acquisition of stock options under a pre-arranged trading plan.

Director John Ketchum received an equity grant of 4,000 restricted stock units and 25,000 stock options from Tango Therapeutics.

Director Lesley Ann Calhoun received an equity grant of 4,000 restricted stock units and 25,000 stock options from Tango Therapeutics.

Director Mace Rothenberg was granted 4,000 restricted stock units and 25,000 stock options by Tango Therapeutics.

Director Sung Lee received an equity grant of restricted stock units and stock options from Tango Therapeutics.

Tango Therapeutics has scheduled its 2026 Annual Meeting of Stockholders for June 4, 2026, to elect directors, ratify auditors, and conduct an advisory vote on executive compensation.

Tango Therapeutics seeks stockholder approval to double its authorized common stock, providing flexibility for future capital raises and strategic initiatives.

Tango Therapeutics is holding its 2025 Annual Meeting, seeking shareholder votes on key proposals including the election of a director, ratification of the auditor, an increase in authorized shares, and executive compensation.

Tango Therapeutics is holding its 2025 Annual Meeting of Stockholders to vote on key proposals, including increasing authorized common stock and executive compensation.

Tango Therapeutics is holding its 2024 Annual Meeting of Stockholders virtually on June 5, 2024, to vote on director elections, auditor ratification, and an amendment to limit officer liability.

Third Rock Ventures has significantly reduced its beneficial ownership in Tango Therapeutics, Inc., now holding approximately 5.85% of common stock.

Third Rock Ventures has significantly reduced its beneficial ownership in Tango Therapeutics, Inc. to 6.97% through multiple open market dispositions.

An amendment to Schedule 13D reveals a restructuring of beneficial ownership in Tango Therapeutics, Inc., with BCTG Holdings, LLC distributing its shares to MVA Investors, LLC and Boxer Capital Management, LLC, while Aaron I. Davis's aggregate beneficial ownership remains at approximately 10%.

Tango Therapeutics, Inc. has filed an amendment to its Schedule 13G, detailing beneficial ownership as of June 30, 2026, with reporting persons holding 0.0% of the class.

TCG Crossover Fund II, L.P., along with affiliated entities and individual Chen Yu, has increased its beneficial ownership in Tango Therapeutics, Inc. to 7.0%, acquiring 10,147,867 shares.

Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC have filed a Schedule 13G, reporting beneficial ownership of 6.0% of Tango Therapeutics, Inc. common stock as of June 30, 2026.

Woodline Partners LP has disclosed a beneficial ownership of 4,000,567 shares, representing 2.5% of the outstanding common stock of Tango Therapeutics, Inc.

Farallon Capital Management and affiliated entities have reported beneficial ownership of 9.8% of Tango Therapeutics' common stock, primarily through warrants and shares.

Adage Capital Management, L.P. and associated individuals have reported beneficial ownership of 5,600,000 shares, representing 3.44% of Tango Therapeutics, Inc. common stock.